Industry Pays The Fees, FDA Should Deliver, Nissen Says Of Missed PDUFA Dates
This article was originally published in The Pink Sheet Daily
Simplified trials and short-term approvals could speed approval of innovative products, according to the Cleveland Clinic physician.
You may also be interested in...
Speculation about the next FDA head is well under way, but before it gets out of hand, here are five rules of thumb to keep in mind.
FDA's ability to meet its Prescription Drug User Fee Act deadlines for new product approvals may end up below the agency's earlier estimates, according to Office of New Drugs Director John Jenkins
Cardiovascular risks identified in a meta-analysis by Steven Nissen prompt immediate announcements of an advisory committee meeting and congressional investigations.